⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RAPP News
Rapport Therapeutics, Inc. Common Stock
Rapala VMC’s Q3/2026: North America remained robust while large parts of Europe faced a challenging drought situation
globenewswire.com
RAPP
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
globenewswire.com
RAPP
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
globenewswire.com
RAPP
Form 8-K
sec.gov
RAPP
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
globenewswire.com
RAPP
Rapport Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
RAPP
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
globenewswire.com
RAPP
Rapala VMC’s H1/2026: Strong dynamics in North America led to improved sales and profitability
globenewswire.com
RAPP
Inside information: Rapala VMC Corporation issues a positive profit warning: expects full year comparable operating profit to be in the range of 12 to 14 MEUR
globenewswire.com
RAPP
Form 8-K
sec.gov
RAPP